A biomedical scientist is hanging up her white coat after more than four decades in pathology – after initially applying for ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

A new scholarship in the name of one of the University of Tasmania's most innovative and inspirational alumni will support ...

A ferry wharf linking the new Sydney Fish Market is among $70 million in proposed transport upgrades announced on Monday.

Tasmanian Senator Jacqui Lambie has slammed the NDIS over its Annual Pricing Review, calling it a “betrayal.” The review was ...

US biotech fund BVF Parners has sold its stake in drug developer Syntara, thus exiting all of its ASX life sciences exposures ...

But a new blood test promises to change all that, researchers reported. The test looks for a specific immune response to ...

BEVERLY HILLS, CA / ACCESS Newswire / June 18, 2025 / World-renowned spinal neurosurgeon and motion preservation expert Dr.

A medtech that raised $6m is tapping investors again to expand its hyper-realistic human models that allow cost-effective ...

Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule ...

Most climate responses continue to treat the symptoms, not the cause. But what if the solution isn't more, but less?

Results of an autopsy-based study revealed that sudden cardiac death and multiorgan pathology may be more closely linked to SSc than previously thought.